Livzon Pharmaceutical

Focus: Livzon Pharmaceutical is a China-based generics, traditional medicines, and API manufacturer with a diversified pipeline spanning infectious diseases, oncology, gastroenterology, immunology, and respiratory indications. The company operates from Zhuhai and maintains an active clinical development program across multiple therapeutic areas.

Infectious Diseases Oncology Gastroenterology Immunology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Livzon Pharmaceutical

AI assessmentNot Hiring

No open roles listed right now. Follow Livzon Pharmaceutical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthStrong

Pipeline

Late-stage

8 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Recombinant SARS-CoV-2 Fusion Protein Vaccine

COVID-19 Pandemic

N/A

Clinical Trials (1)

NCT05125874Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization

N/A

Help build intelligence for Livzon Pharmaceutical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Diversified pipeline of 30 programs across Phase 1-4, including COVID-19 vaccines, oncology candidates (anti-PD-1 mAb, solid tumor therapies), and established gastroenterology franchises
Strong focus on infectious diseases and oncology with multiple Phase 3 programs nearing commercialization providing advancement opportunities
Established generics and traditional medicine business provides revenue stability while early-stage programs offer innovation exposure

Watch Out For

No active job openings reported and limited transparency on hiring, suggesting restricted growth or external recruitment freeze
Heavy concentration on generics and traditional medicines limits exposure to cutting-edge modalities; pipeline quality unclear with multiple Phase 1 programs and limited published data

Generated by Claude from Livzon Pharmaceutical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

shenqifuzheng injection

Carcinogenic Fatigue

N/A

Clinical Trials (1)

NCT03456609Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Patients(BCS) With Digestive Tract .

N/A

shenqifuzheng

Digestive Tract

N/A

Clinical Trials (1)

NCT03455205Shenqi Fuzheng Injection for the Treatment of Cancer-related Fatigue in Chemo Patients With Digestive Tract .

N/A

SQ001 125mL/day

Solid Tumor Refractory to Standard Therapy

Phase 1

Clinical Trials (1)

NCT04026321Single-dose Escalation Study of SQ-001 Infusion to Characterize the PK Profiles of Major Sentinel Compounds in Healthy Adult Volunteers in US

Phase 1

V-01D-351

COVID-19 Pandemic

Phase 1

Clinical Trials (1)

NCT05583357Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

Phase 1

DBM-1152A Inhalation Solution

Health

Phase 1

Clinical Trials (1)

NCT07447141DBM-1152A Inhalation Solution in Chinese Healthy Subjects

Phase 1

LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection

Solid Tumor

Phase 1

Clinical Trials (1)

NCT03286296LZM009 to Treat Patients With Advanced Solid Tumors

Phase 1

Recombinant SARS-CoV-2 Fusion Protein Vaccine

COVID19

Phase 1

Clinical Trials (1)

NCT05050474Booster Immunization Study of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01)

Phase 1

V-01/V-01-B5

COVID-19 Pandemic

Phase 1

Clinical Trials (1)

NCT05585567A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5

Phase 1

DBM-1152A

Healthy

Phase 1

Clinical Trials (1)

NCT07439419DBM-1152A Inhalation Solution in Healthy Volunteers

Phase 1

Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg

COVID-19 Pandemic

Phase 2

Clinical Trials (1)

NCT05238649Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine

Phase 2

10 mg ilaprazole

Gastroesophageal Reflux Disease

Phase 2

Clinical Trials (1)

NCT01107938Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Phase 2

JKN2304 Inhalation Solution

COPD (Chronic Obstructive Pulmonary Disease)

Phase 2

Clinical Trials (1)

NCT07450482Safety and Efficacy of JKN2304 Inhalation Solution in Patients With Moderate to Severe COPD

Phase 2

Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine

COVID-19 Pandemic

Phase 2

Clinical Trials (1)

NCT05273528The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine

Phase 2

Ilaprazole

Peptic Ulcer Hemorrhage

Phase 2

Clinical Trials (1)

NCT03362268IIaprazole for the Treatment and Prevention of Peptic Ulcer Bleeding in Chinese Patients

Phase 2

Recombinant SARS-CoV-2 Fusion Protein Vaccine

COVID-19 Pandemic

Phase 2

Clinical Trials (1)

NCT05239832Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

Phase 2

5 mg ilaprazole

Duodenal Ulcer

Phase 2

Clinical Trials (1)

NCT00953381Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients (Phase 2)

Phase 2

H001 Capsule 200mg-qd

Circulatory Disease

Phase 2

Clinical Trials (1)

NCT06963320Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty

Phase 2

5 mg ilaprazole

Duodenal Ulcer

Phase 2/3

Clinical Trials (1)

NCT02847455Ilaprazole for the Treatment of Duodenal Ulcer in Chinese Patients

Phase 2/3

Recombinant SARS-CoV-2 Fusion Protein Vaccine

COVID-19 Pandemic

Phase 3

Clinical Trials (1)

NCT05096832Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Study

Phase 3

Esomeprazole 40mg

Stress Ulcer Bleeding

Phase 3

Clinical Trials (1)

NCT05841394A Multi-center, Double-blinding, Parallel and Positive-controlled Phase III Clinical Trial for Efficacy and Safety Evaluation of Ilaprazole Sodium for Injection on Prevention of Stress Ulcer Bleeding

Phase 3

10 mg ilaprazole

Gastroesophageal Reflux Disease

Phase 3

Clinical Trials (1)

NCT02860624Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients

Phase 3

LZM012

Psoriasis

Phase 3

Clinical Trials (1)

NCT06110676A Study to Evaluate the Efficacy and Safety of LZM012